Mebendazole
Emverm (mebendazole) is a small molecule pharmaceutical. Mebendazole was first approved as Vermox on 1982-01-01. It is used to treat ancylostomiasis, ascariasis, enterobiasis, helminthiasis, and trichuriasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Emverm (discontinued: Vermox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mebendazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VERMOX | Johnson & Johnson | N-017481 DISCN | 1982-01-01 | 1 products, RLD |
| VERMOX | Johnson & Johnson | N-208398 DISCN | 2016-10-19 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| emverm | ANDA | 2021-08-23 |
| mebendazole | ANDA | 2010-04-29 |
| vermox | New Drug Application | 2021-10-05 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | 1 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 1 | — | — | — | 1 |
| Gliosarcoma | D018316 | — | — | 1 | 1 | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | 1 | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | 1 | 1 | — | — | — | 1 |
| Optic nerve glioma | D020339 | — | — | 1 | 1 | — | — | — | 1 |
| Brain stem neoplasms | D020295 | EFO_1001767 | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mebendazole |
| INN | mebendazole |
| Description | Mebendazole is a carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5. It has a role as an antinematodal drug, a tubulin modulator and a microtubule-destabilising agent. It is a member of benzimidazoles, a carbamate ester and an aromatic ketone. It derives from a hydride of a 1H-benzimidazole. |
| Classification | Small molecule |
| Drug class | antithelmintics (tibendazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)Nc1nc2cc(C(=O)c3ccccc3)ccc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 31431-39-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL685 |
| ChEBI ID | 6704 |
| PubChem CID | 4030 |
| DrugBank | DB00643 |
| UNII ID | 81G6I5V05I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Mebendazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,931 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
778 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use